Medicinal Products

517. Deputy Ken O'Flynn asked the Minister for Health further to the HSE's confirmation that no national dataset on returned medicines currently exists, whether the national medicines disposal service under CPA25 will record returned medicines as a defined, structured national dataset; to specify the data fields that dataset will capture; and if she will make a statement on the matter. [50611/26]

518. Deputy Ken O'Flynn asked the Minister for Health whether data on the volume, type and cost of medicines returned under the CPA25 disposal service will be published; the frequency of such publication; the date on which the first such report will issue; and if she will make a statement on the matter. [50612/26]

519. Deputy Ken O'Flynn asked the Minister for Health the confirmed commencement date of the national medicines disposal service under CPA25, given the HSE's statement that the service is due to commence "over the summer" in 2026; and if she will make a statement on the matter. [50613/26]

520. Deputy Ken O'Flynn asked the Minister for Health whether a baseline estimate of the annual cost of unused, expired or otherwise wasted medicines will be established at the commencement of the CPA25 disposal service; the methodology to be applied; and if she will make a statement on the matter. [50614/26]

521. Deputy Ken O'Flynn asked the Minister for Health whether waste-reduction targets will be set on foot of the data collected under the CPA25 disposal service; the office responsible for owning and governing that dataset; whether that dataset features on any HSE risk register or audit plan; and if she will make a statement on the matter. [50615/26]

528. Deputy John McGuinness asked the Minister for Health if she will provide an update on the approval of the drug skyclarys in the reimbursement scheme; if all of the information and costings have been submitted by the supplier; and the indicative date for approval. [50630/26]

548. Deputy Mark Ward asked the Minister for Health if belzutifan will be made available to people with Von Hippel-Lindau disease; the steps being taken to make this therapy available; and if she will make a statement on the matter. [50755/26]

789. Deputy Ken O'Flynn asked the Minister for Health further to Parliamentary Question No. 2547 of 9 June 2026, the number of the 12,899 respiratory medicine claims rejected under the PCRS between 2023 and 2026 to date, that remain unpaid following resubmission; the breakdown of this unrecovered figure, by year and, by rejection reason; the steps her Department and the HSE are taking to address t…

807. Deputy Conor Sheehan asked the Minister for Health when the current review of the core list of medications under the long-term illness scheme will be completed; the way in which a drug can be put forward for consideration under this review; and if she will make a statement on the matter. [49053/26]

825. Deputy Niamh Smyth asked the Minister for Health to review the case of a person (details supplied); if she can provide an update on the drug with regards to the medical card system; and if she will make a statement on the matter. [49199/26]

902. Deputy Conor Sheehan asked the Minister for Health if the NCPE is evaluating the application of mounjaro and wegovy for severe metabolic and endocrine conditions alongside obesity; and if she will make a statement on the matter. [49595/26]

903. Deputy Conor Sheehan asked the Minister for Health the number of validated applications submitted by clinicians for Glucagon-like peptide-1, GLP-1, therapies under the drugs payment scheme that were rejected by the primary care reimbursement service, PCRS, system on account of diabetes only automated controls; and if she will make a statement on the matter. [49596/26]

925. Deputy Pat Buckley asked the Minister for Health if a treatment (details supplied) can be made available under the medical card and the drugs payment scheme. [49703/26]

414. Deputy Paul McAuliffe asked the Minister for Health if she will consider approving the payment of off-label low dose naltrexone as part of the drugs payment scheme for the treatment of long-Covid patients; and if she will make a statement on the matter. [48375/26]

421. Deputy Albert Dolan asked the Minister for Health if she will provide an update on the consideration by the HSE senior leadership team of the reimbursement application for givinostat; whether a decision has now been reached following the recommendation submitted by the Drugs Group on 9 June 2026; and if she will make a statement on the matter. [48421/26]

466. Deputy Albert Dolan asked the Minister for Health the reason skyclarys has not been included on the agenda for the recent HSE Drugs Group meeting held in June 2026; when the drug will be considered by the Drugs Group; the timeline for a decision on its prioritisation within the reimbursement process; and the measures being taken to ensure there are no further avoidable delays in progressing a…

504. Deputy David Cullinane asked the Minister for Health the estimated cost of reducing the drug payment scheme threshold to €60, €40, €20, €15, €10, €5 and €0, in tabular form. [48653/26]

514. Deputy David Cullinane asked the Minister for Health the estimated cost of a 10% uplift in spending on new medicines. [48663/26]

540. Deputy Paul Lawless asked the Minister for Health the reason a necessary prescribed medication (MoviPrep), which is required to prepare a patient for a colonoscopy procedure, is not covered under the medical card scheme; if her attention has been drawn to the financial burden this places on patients in receipt of disability allowance or other social welfare supports; and her plans to review o…

273. Deputy Naoise Ó Cearúil asked the Minister for Health whether consideration will be given, as part of the ongoing review of medicines reimbursement, to strengthen and formalise the role of the Rare Disease Technology Review Committee; whether she will consider ensuring its early, consistent and structured involvement alongside the health technology assessment process in order to improve timel…

711. Deputy David Cullinane asked the Minister for Health the target and actual generic substitution rate for each health region; and her plans for improving generic substitution and improvements in medicines spending efficiency. [47075/26]

727. Deputy Shane Moynihan asked the Minister for Health when a drug treatment for neurofibromatosis (details supplied) will be made available for patients by the HSE. [47109/26]

728. Deputy Shane Moynihan asked the Minister for Health when a drug treatment for neurofibromatosis (details supplied) will be made available for patients by the HSE. [47110/26]

729. Deputy Conor Sheehan asked the Minister for Health if she plans to broaden the reimbursement criteria for GLP-1 medications, such as ozempic, under the drugs payment scheme or long-term illness scheme to include patients diagnosed with metabolic disorders, including polycystic metabolic syndrome and polycystic ovary syndrome, where insulin resistance is a core clinical symptom; her views on w…

739. Deputy Erin McGreehan asked the Minister for Health the status of negotiations regarding belzutifan, noting that the HSE is currently engaged in pricing discussions with a company (details supplied).; and if she will make a statement on the matter. [47251/26]